100-OR: A Novel Macrophage-Regulation Drug for Treating Diabetic Foot Ulcer—A Phase III MRCT Study and Taiwan Experience

医学 糖尿病足溃疡 糖尿病足 内科学 不利影响 截肢 药品 入射(几何) 伤口愈合 外科 糖尿病 药理学 光学 物理 内分泌学
作者
SHYI-GEN CHEN,SHUN-TIEN CHU,Chi‐Ming Pu,JUI-CHING CHEN,YI-HSIN WU
出处
期刊:Diabetes [American Diabetes Association]
卷期号:72 (Supplement_1) 被引量:3
标识
DOI:10.2337/db23-100-or
摘要

Macrophage regulation plays an essential role in Diabetic foot ulcer (DFU) healing. By recognizing the therapeutic potential in M1/M2-macrophage-regulation for DFUs, we aim to investigate the efficacy and safety of ON101, a topical new drug with a M1/M2-macrophage-regulating mechanism in phase 3 MRCT across the US, China, and Taiwan (NCT01898923). There are 236 eligible subjects with Wagner Grade 1 or 2 DFU(s), randomized 1:1 to receive ON101 or comparator for up to 16 weeks, followed by a 12-week follow-up. The incidence of complete healing was 60.7% by ON101 and 35.1% by the comparator (P=0.0001). The time to complete ulcer healing was faster in the ON101 group (P=0.002). Since the high levels of HbA1C, ulcer persistence, ulcer location, and amputation history as the risk factors leading to poor DFU outcomes, ON101 also showed demonstrated robust efficacy and safety in hard-to-heal ulcers. ON101, approved by Taiwan FDA in 2021, was shown with excellent therapeutic efficacy and safety in the treatment of DFUs. In a real-world scenario, case collation from 133 patients, ulcer severity with Wagner grade 1 to 4, after applying ON101, the average ulcer complete healing rate is 71%, no adverse events were related to ON101, which validates the drug safety of ON101. ON101 further supports its excellent ability to promote wound healing in DFU patients with various severities (Wagner grade 1 to 4). All those patients who applied ON101 alone or with other therapies reached ulcer healing under infection control and with necessary debridement. Macrophage-regulating drug achieved superior therapeutic efficacy in a large Phase 3 MRCT and has demonstrated excellent therapeutic efficacy in the real-world scenario where Wagner grade 3 and 4 DFUs reached ulcer healing when ON101 was combined with other therapies. This enlightens the future treatment in Wagner grade 1 to 4 DFUs by macrophage immunomodulation new drug as a promising solution. Disclosure S.Chen: Employee; Oneness Biotech Co., Ltd. S.Chu: None. C.Pu: None. J.Chen: Employee; Oneness Biotech Company. Y.Wu: Employee; Oneness Biotech Co., Ltd.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
Rtian完成签到,获得积分10
1秒前
SUNstp发布了新的文献求助10
1秒前
酷酷李可爱婕完成签到 ,获得积分0
1秒前
h_jun完成签到 ,获得积分10
1秒前
kaida完成签到,获得积分10
1秒前
923完成签到,获得积分10
1秒前
yuan发布了新的文献求助10
1秒前
1秒前
djdj放技能完成签到 ,获得积分10
1秒前
1秒前
任11完成签到 ,获得积分10
2秒前
奋斗信封完成签到,获得积分10
2秒前
chijiadong完成签到,获得积分20
3秒前
3秒前
小胖完成签到,获得积分10
3秒前
Akim的应助被阿飞采纳,获得10
3秒前
4秒前
大石完成签到,获得积分10
4秒前
啪叽米完成签到 ,获得积分10
4秒前
武陵济世发布了新的文献求助10
5秒前
雨过天晴发布了新的文献求助10
5秒前
科研通AI6.4的应助被Borky采纳,获得10
5秒前
5秒前
5秒前
关月明完成签到,获得积分10
6秒前
6秒前
Owen的应助被aqqq采纳,获得10
6秒前
哒哒哒哒哒哒完成签到,获得积分10
6秒前
6秒前
orixero的应助被刘宇采纳,获得10
6秒前
geold发布了新的文献求助10
6秒前
自然亦寒完成签到,获得积分10
6秒前
DW的应助被benihikari采纳,获得10
7秒前
shenwomiss完成签到,获得积分10
7秒前
7秒前
田様的应助被哈密瓜牛奶采纳,获得10
7秒前
7秒前
7秒前
听见完成签到,获得积分10
7秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180586
求助须知:如何正确求助?哪些是违规求助? 9570581
关于积分的说明 21813457
捐赠科研通 7776777
什么是DOI,文献DOI怎么找? 3433294
关于科研通互助平台的介绍 2557547
邀请新用户注册赠送积分活动 2479253